NCT04533958Completed
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy Monocentric, Comparative, Randomized, Open Study
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
Prostate cancer is the first cancer in men. The treatment of metastatic prostate cancer with chemotherapy is based on the intravenous administration of docetaxel chemotherapy. Symptoms of anticipatory nausea, linked to anxiety caused by the treatment, may occur. Hypnosis is already used to treat the anxiety of people with cancer and can help treat the symtoms of nausea and vomiting of women with breast cancer. The purpose of the study is to evaluate the effect of medical hypnosis in virtual reality on the anxiety of patients with metastatic prostate cancer receiving Docetaxel chemotherapy treatment in comparison with a control group.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 53 (actual)
- First submitted
- 11 Aug 2020
- Start date
- 28 Sept 2020
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Saint-Gregoire Private Hospital Center
- Diseases
- Prostate cancer
- NCT number
- NCT04533958
What you commit to
- Study type: Interventional
- Participants enrolled: 53
- From 28 Sept 2020 to the primary completion date, 31 Dec 2025
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who received previous chemotherapy
- Patient with underlying or concomitant pathology incompatible with inclusion in the trial, whether psychiatric or somatic
Other
- Patient participating in another clinical trial on an experimental molecule
- Patient unable to submit to protocol monitoring for psychological, social, family or geographic reasons
- Patient deprived of their liberty or under guardianship
Who the study is looking for
- Man aged ≥ 18 years
- Histologically proven metastatic prostate adenocarcinoma,
- Patient undergoing chemotherapy according to the following conventional scheme: 12 courses of Docetaxel every two weeks
- Patient who signed their informed consent
- Patient benefiting from social security coverage
- Patient treated and followed in the center for the duration of the study (6 months maximum).
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinique Pasteur Lanroze Coordinator of this site? Confirm its status | Brest | France | Unknown status |
| CHP Saint Grégoire Coordinator of this site? Confirm its status | Saint-Grégoire | France | Unknown status |
| Clinique de la Côte d'Emeraude Coordinator of this site? Confirm its status | St-Malo | France | Unknown status |
| Hospital Lusiadas Amadora Coordinator of this site? Confirm its status | Amadora | Portugal | Unknown status |
| Hospital Lusíadas Lisboa Coordinator of this site? Confirm its status | Lisbon | Portugal | Unknown status |
| Hospital Lusiadas Porto Coordinator of this site? Confirm its status | Porto | Portugal | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.